Assessing the Impact of Losmapimod on Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis

Idiopathic focal segmental glomerulosclerosis (FSGS) is a leading cause of nephrotic syndrome and end-stage renal disease. In preclinical models and biopsies of human FSGS kidneys, p38 mitogen-activated protein kinase (MAPK) has demonstrated enhanced activity; and p38 MAPK inhibition has improved di...

Full description

Saved in:
Bibliographic Details
Published in:Kidney international reports 2020-08, Vol.5 (8), p.1228-1239
Main Authors: Gipson, Debbie S., Hladunewich, Michelle A., Lafayette, Richard, Sedor, John R., Rovin, Brad H., Barbour, Sean J., McMahon, Alan, Jennette, J. Charles, Nachman, Patrick H., Willette, Robert N., Paglione, Marcella, Gao, Feng, Ross Terres, Jorge Alfonso, Vallow, Sue, Holland, M. Claire, Thorneloe, Kevin S., Sprecher, Dennis L.
Format: Article
Language:English
Subjects:
Clinical Research
clinical trial
FSGS
glomerulosclerosis
nephrotic syndrome
proteinuria
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Idiopathic focal segmental glomerulosclerosis (FSGS) is a leading cause of nephrotic syndrome and end-stage renal disease. In preclinical models and biopsies of human FSGS kidneys, p38 mitogen-activated protein kinase (MAPK) has demonstrated enhanced activity; and p38 MAPK inhibition has improved disease markers. This proof-of-concept trial aimed to assess efficacy, safety, tolerability, and pharmacokinetics of losmapimod, an oral p38 MAPK inhibitor, in humans with FSGS. A single-arm, multicenter, open-label, Phase II trial (NCT02000440) was conducted in adults with FSGS; proteinuria ≥2.0 g/d; estimated glomerular filtration rate (eGFR) ≥45 ml/min per 1.73 m2; blood pressure 
ISSN:2468-0249
2468-0249
DOI:10.1016/j.ekir.2020.05.024